HC Wainwright Cuts Jasper Therapeutics (NASDAQ:JSPR) Price Target to $40.00

Jasper Therapeutics (NASDAQ:JSPR) had its price objective trimmed by HC Wainwright from $60.00 to $40.00 in a research note published on Friday,Benzinga reports. The firm currently has a buy rating on the stock. HC Wainwright also issued estimates for Jasper Therapeutics’ Q1 2025 earnings at ($1.48) EPS, Q2 2025 earnings at ($1.63) EPS, Q3 2025 earnings at ($1.78) EPS, Q4 2025 earnings at ($1.93) EPS, FY2025 earnings at ($6.83) EPS, FY2026 earnings at ($8.17) EPS, FY2027 earnings at ($9.50) EPS, FY2028 earnings at ($10.61) EPS and FY2029 earnings at ($10.81) EPS.

JSPR has been the topic of several other reports. BMO Capital Markets assumed coverage on Jasper Therapeutics in a report on Friday, December 6th. They set an “outperform” rating and a $63.00 target price on the stock. JMP Securities reissued a “market outperform” rating and set a $70.00 target price on shares of Jasper Therapeutics in a research note on Monday, January 6th. Finally, Royal Bank of Canada cut their price target on Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating on the stock in a report on Thursday. Ten investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $67.75.

Jasper Therapeutics Trading Up 0.9 %

Shares of JSPR stock opened at $7.05 on Friday. The business’s 50-day moving average price is $21.09 and its 200-day moving average price is $20.15. Jasper Therapeutics has a 12 month low of $6.57 and a 12 month high of $31.01. The firm has a market capitalization of $105.76 million, a price-to-earnings ratio of -1.49 and a beta of 2.18.

Institutional Investors Weigh In On Jasper Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. boosted its holdings in shares of Jasper Therapeutics by 239.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 16,391 shares of the company’s stock worth $308,000 after buying an additional 11,567 shares during the last quarter. Barclays PLC grew its position in shares of Jasper Therapeutics by 320.7% during the 3rd quarter. Barclays PLC now owns 16,146 shares of the company’s stock valued at $304,000 after purchasing an additional 12,308 shares in the last quarter. Jane Street Group LLC bought a new position in Jasper Therapeutics in the 3rd quarter worth about $251,000. Wellington Management Group LLP bought a new position in shares of Jasper Therapeutics in the third quarter worth approximately $447,000. Finally, State Street Corp increased its holdings in shares of Jasper Therapeutics by 12.3% in the 3rd quarter. State Street Corp now owns 214,883 shares of the company’s stock worth $4,042,000 after buying an additional 23,564 shares during the last quarter. 79.85% of the stock is owned by institutional investors.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.